Tag: BCR

[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy]

Objective: To explore the prognostic value of circulating tumor DNA (ctDNA) testing in patients with refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy, and to guide the prevention and subsequent treatment of CAR-T-cell therapy failure. Methods: In this study, 48 patients with R/R DLBCL…

Continue Reading [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy]

Precision Medicine: A New Era in Cancer Therapy

Precision medicine can offer improved clinical outcomes by assessing the unique characteristics of tumors, such as their likelihood of developing resistance to chemotherapy. Stay up to date on the latest science with Brush Up Summaries.  Precision Medicine in Cancer Precision medicine for cancer treatment involves tailoring treatments to an individual…

Continue Reading Precision Medicine: A New Era in Cancer Therapy

Formononetin | FGFR2 inhibitor | Axon 4067

All All Products Enzymes Receptors Ion Channels Research Areas Oxidoreductases Transferases Lyases Isomerases Ligases Nuclear Receptors Ligand-gated ATP-Sensitive Angiogenesis Apoptosis Cardiovascular Cell Cycle Regulation Cell Signaling & Oncology CNS Diabetes & Metabolism Epigenetics Immunology Miscellaneous Pain & Inflammation Stem Cell Oxidases MAO Cys-loop, cationic Cis-Trans Isomerase CypA DNA Topoisomerase Synthetases…

Continue Reading Formononetin | FGFR2 inhibitor | Axon 4067

Comprehensive Review of Small Interfering RNAs (siRNAs)

Introduction Cancer, also called malignancy, is a group of diseases caused by the rapid multiplication and spread of malignant cells.1,2 According to statistics from the National Cancer Center, more than 100 types of cancer have been identified.3 The ability of malignant tumor cells to metastasize via the blood-lymphatic system and…

Continue Reading Comprehensive Review of Small Interfering RNAs (siRNAs)

What is B-Cell Receptor Repertoire Sequencing?

What is BCR-seq? B cell receptor sequencing (BCR-seq) represents an advanced and rapid method for the exhaustive detection of target-amplified B-cell receptors (BCRs) through the integration of high-throughput sequencing technology and bioinformatics. By scrutinizing the abundance of each sequence, BCR-seq unveils the intricacies of B-cell-mediated humoral immune responses and the…

Continue Reading What is B-Cell Receptor Repertoire Sequencing?

Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications

Agarwal P, Kabir FM, DeInnocentes P, Bird RC (2012) Tumor suppressor gene p16/INK4A/CDKN2A and its role in cell cycle exit, differentiation, and determination of cell fate. Tumor Suppressor Genes 3(10):27882 Google Scholar  Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E et al (2022) The 5th edition…

Continue Reading Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications

Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study

Genetic characterization For risk stratification and identification of genetic aberrations suitable as MRD targets, diagnostic material from 133 children with primary AML was examined (see “Methods” and Supplementary Table 3). The presence of selected fusion genes and mutations was prospectively investigated using (q)RT-PCR and sequencing. A primary genetic aberration was found…

Continue Reading Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study

Exploring potential therapeutic agents for lipopolysaccharide-induced septic cardiomyopathy based on transcriptomics using bioinformatics

Cohen, J. et al. Sepsis: A roadmap for future research. Lancet Infect. Dis. 15, 581–614 (2015). Article  PubMed  Google Scholar  L’Heureux, M., Sternberg, M., Brath, L., Turlington, J. & Kashiouris, M. G. Sepsis-induced cardiomyopathy: A comprehensive review. Curr. Cardiol. Rep. 22, 35 (2020). Article  PubMed  Google Scholar  Ravikumar, N. et…

Continue Reading Exploring potential therapeutic agents for lipopolysaccharide-induced septic cardiomyopathy based on transcriptomics using bioinformatics

how to get ER, PR and HER2 data from TCGA BRCA

how to get ER, PR and HER2 data from TCGA BRCA 2 Hi I have dowloaded the BRCA data from TCGA using TCGABiolinks I have done this: BRCARnaseqSE <- GDCprepare(query.a, directory = “BRCA_all”) sample.info <- SummarizedExperiment::colData(BRCARnaseqSE) Now I want to get data on ER, PR and HER2 – positive, negative…

Continue Reading how to get ER, PR and HER2 data from TCGA BRCA

Xtandi Gains Approval for Nonmetastatic Castration-Sensitive Prostate Cancer

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Xtandi® (enzalutamide) for the treatment of patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).  The approval was based on data from the phase 3 EMBARK trial…

Continue Reading Xtandi Gains Approval for Nonmetastatic Castration-Sensitive Prostate Cancer

Singleron Biotechnologies announces two co-authored abstracts at the American Society of Hematology conference

Using single cell multi-omics analysis to predict treatment outcome, develop disease prognostics and track patient responses to CAR T therapies COLOGNE, Germany, Nov. 17, 2023 /PRNewswire/ — Singleron Biotechnologies, a company at the forefront of developing and commercializing innovative single cell multi-omic analysis solutions for precision medicine, has announced two…

Continue Reading Singleron Biotechnologies announces two co-authored abstracts at the American Society of Hematology conference

New assay could revolutionize detection and treatment of acute myeloid leukemia

Design of droplet digital PCR (ddPCR) assay. A: Schematic of ddPCR assay. Primers spanned the fusion break points (KMT2A-AF4 depicted). Nested fluorescently labeled probes recognized unique sequences in KMT2A (FAM) and the fusion partner AFF1-AF4 (HEX). B: Example ddPCR result depicting double-positive droplets containing cDNA with an oncogenic KMT2A fusion…

Continue Reading New assay could revolutionize detection and treatment of acute myeloid leukemia

Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene

Introduction The ETV6::PDGFRB fusion gene is commonly associated with myeloid neoplasms with monocytosis (such as CMML), and with eosinophilia.1 The PDGFRB gene, located on 5q33, encodes PDGFRβ, a type III tyrosine kinase comprising an extracellular domain consisting of five immunoglobulin (Ig)-like domains, a single-transmembrane helix domain, a juxtamembrance domain, and…

Continue Reading Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Oral and Poster Abstracts 652. Multiple Myeloma: Clinical and Epidemiological: Poster III Research, adult, Translational Research, assays, Plasma Cell Disorders, bioinformatics, Diseases, Lymphoid Malignancies, computational biology, Technology and Procedures, Study Population, Human, molecular testing, omics technologies Dor D. Abelman1,2, Jenna Eagles1*, Stephanie Pedersen1*,…

Continue Reading Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE

Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations MINNEAPOLIS , Nov. 2, 2023 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer…

Continue Reading ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE

The Age of Aquarius – RNA, the Epicenter of Genetic Information

The veil on genetic information was lifted by the advent of gene cloning and sequencing technologies in the 1970s. The discovery and purification of bacterial nucleases capable of cutting DNA at specific sequences and ligases capable of joining them enabled DNA from any species – or mRNAs converted to complementary…

Continue Reading The Age of Aquarius – RNA, the Epicenter of Genetic Information

A spatial sequencing atlas of age-induced changes in the lung during influenza infection

Single-cell RNA sequencing reveals cellular heterogeneity among young and aged lungs post-influenza infection In order to investigate age-induced alterations in the host response to influenza A virus (IAV) infection, we infected groups of three young (16–18-week-old) and three aged (80–82-week-old) female C57Bl/6 mice intranasally with 50 PFU of the PR8…

Continue Reading A spatial sequencing atlas of age-induced changes in the lung during influenza infection

Enzalutamide data published in NEJM as FDA weighs nonmetastatic HSPC approval

Data from the phase 3 EMBARK trial supporting a potential FDA approval of enzalutamide (Xtandi) for nonmetastatic hormone-sensitive prostate cancer (nmHSPC) have been published in the New England Journal of Medicine.1,2 The 5-year MFS rate 87.3% for those treated with enzalutamide plus leuprolide compared with 71.4% for those given leuprolide…

Continue Reading Enzalutamide data published in NEJM as FDA weighs nonmetastatic HSPC approval

To genetically characterize Fasciola adult worms

Introduction Fascioliasis is a zoonotic disease of public health significance and a worldwide distribution.1 The causative agents of Fascioliasis are F. hepatica (F. hepatica; temperate liver fluke) and Fasciola gigantica (tropical liver fluke).2,3 Although it has been recognized for centuries, the disease is currently expanding and has a serious impact…

Continue Reading To genetically characterize Fasciola adult worms

SeqMatic Adds Visium Spatial Gene Expression to its 10x Genomics Certified Service Provider Portfolio

Fremont, California – October 2nd, 2023 – SeqMatic, a leading provider of next-generation sequencing (NGS) and omics services, is proud to announce that it has received Visium Spatial Gene Expression and Visium Spatial Gene Expression for FFPE Certifications from 10x Genomics. These certifications further demonstrate SeqMatic’s commitment to delivering efficient…

Continue Reading SeqMatic Adds Visium Spatial Gene Expression to its 10x Genomics Certified Service Provider Portfolio

Human Perspectives Question 5001 Mutations in what kind of genes cause the cells

255.Human Perspectives Question 5.003 What happened to mice injected intravenously with an siRNA that targets and destroys Fas mRNA? A)They die. B)They become relatively resistant to the development of fulminant hepatitis. C)They grow less hair. D)They develop virulent fulminant hepatitis. E)Their livers enlarge. Ans: B Difficulty: Medium Human Perspectives 256.Human…

Continue Reading Human Perspectives Question 5001 Mutations in what kind of genes cause the cells

Recent research in prostate cancer: Breakthroughs and innovations

Prostate cancer is the second most commonly occurring cancer in men. More than 1.4 million people were diagnosed with prostate cancer in 2020, according to the World Cancer Research Fund International. While some prostate cancers develop too slowly, to the extent that some people will not need any treatment during…

Continue Reading Recent research in prostate cancer: Breakthroughs and innovations

Learning the rules of the Scrabble game behind lymphocyte diversity

Reporter, terrier, retire, retro, port, trio, toe. What do these seemingly random words have in common? They can all be formed from bits and pieces of the word repertoire (hats off to any Scrabble fans in the audience). This concept—of adding, deleting, and rearranging the letters of a fixed character…

Continue Reading Learning the rules of the Scrabble game behind lymphocyte diversity

How to run TRUST4 for BCR/TCR detection using 10X data?

I’m trying to follow this tutorial here: github.com/liulab-dfci/TRUST4#10x-genomics-data-and-barcode-based-single-cell-data However, I’m not sure how to adapt my data. I have R1 reads that look like this where the reads are 28 bp long: @A00588:95:H2H5KDRX3:1:1101:1163:1000 1:N:0:GTAACATGCG+AGGTAACACT AGCTATCTACTTCTGGTACAACCCACTN + FFFF,FFFFF:FFFFFFF:FF:FFFFF# @A00588:95:H2H5KDRX3:1:1101:1904:1000 1:N:0:GTAACATGCG+AGGTAACACT My R2 reads look like this and they 90 bp long:…

Continue Reading How to run TRUST4 for BCR/TCR detection using 10X data?

Genetic Cancer Hereditary Cancer Mutations Susceptibility To Cancer Genetic Changes

Genetic Cancers: Welcome back to “The Science Of Health”, ABP Live’s health column. Last time, in the health column, we discussed the difference between small cell lung cancers and non-small cell lung cancers, and explained why small cell lung cancers are less common than non-small cell lung cancers, despite the…

Continue Reading Genetic Cancer Hereditary Cancer Mutations Susceptibility To Cancer Genetic Changes

BDUK Analysis Shows Benefits of UK Phase 3 Superfast Broadband Project

The Government has posted an updated State Aid evaluation of the previous ‘Superfast Broadband Programme’ (UK National Broadband Scheme), which specifically examines the final Phase 3 of the project to extend “superfast” (30Mbps+) coverage – run between 2016 and 2022. Suffice to say, it finds various economic and coverage benefits….

Continue Reading BDUK Analysis Shows Benefits of UK Phase 3 Superfast Broadband Project

Bioinformatics Fellow (CDC) job in Atlanta, GA at Oak Ridge Associated Universities @ Get.It

Job Reference Code: CDC-NCEZID-2021-0144 Are you a skilled bioinformatics professional looking to advance your career and make a difference? A unique research opportunity awaits you with the Biotechnology Core Facility Branch (BCFB), Division of Scientific Resources at the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) in collaboration with…

Continue Reading Bioinformatics Fellow (CDC) job in Atlanta, GA at Oak Ridge Associated Universities @ Get.It

Scalp infection caused by Mycobacterium abscessus

1School of Clinical Medicine, Weifang Medical University, Weifang, People’s Republic of China; 2Laboratory of Medical Mycology, Jining No. 1 People’s Hospital, Jining, People’s Republic of China; 3Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC, USA; 4Department of Medical Cosmetology, Jining No. 1 People’s Hospital, Jining, People’s Republic…

Continue Reading Scalp infection caused by Mycobacterium abscessus

ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells

doi: 10.1111/bjh.19018. Online ahead of print. Elaine Y L Chung  1 , Giulio Sartori  1 , Maurilio Ponzoni  2 , Luciano Cascione  1   3 , Valdemar Priebe  1 , Zijun Y Xu-Monette  4 , Xiaosheng Fang  4 , Mingzhi Zhang  4 , Carlo Visco  5 , Alexandar Tzankov  6 , Andrea Rinaldi  1 , Jacopo Sgrignani  7 , Emanuele Zucca  8…

Continue Reading ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Susanibar-Adaniya S, Barta SK. 2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617–29. Article  PubMed  PubMed Central  Google Scholar  Rovira J, Valera A, Colomo L, Setoain X, Rodriguez S, Martinez-Trillos A, et al. Prognosis…

Continue Reading The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Acute liver failure after COVID-19 vaccination

Hrvoje Premec,1 Matea &Zcaron;ivko,2 Maja Miji&cacute;,1 Biljana Jeli&cacute;-Puškari&cacute;,3,4 Miloš Lalovac,1,5 Tajana Filipec Kani&zcaron;aj,1,2 Nikola Sobo&ccaron;an1,2 1Department of Gastroenterology, University Hospital Merkur, Zagreb, Croatia; 2School of Medicine, University of Zagreb, Zagreb, Croatia; 3Department of Pathology and Cytology, University Hospital Merkur, Zagreb, Croatia; 4School of Medicine, Catholic University of Croatia, Zagreb, Croatia;…

Continue Reading Acute liver failure after COVID-19 vaccination

Expanding the Drug Target Universe: How Next-Generation Proteomics Is Transforming Oncology Research

Effective target identification and validation lie at the heart of modern drug discovery. Yet the current repertoire of cancer therapeutics is still focused on a relatively small subset of targets compared with the overall “druggable” biology within cancer cells.   Genetic technologies such as genomics and transcriptomics have opened up…

Continue Reading Expanding the Drug Target Universe: How Next-Generation Proteomics Is Transforming Oncology Research

Is there a way to run MiXCR with fasta sequences

Forum:Is there a way to run MiXCR with fasta sequences 0 I’m trying to perform B cell sequence alignment (VH region) using MiXCR, but according to the documentation I’ve read, it requires raw fastq.gz reads. I attempted to use fasta sequences instead of raw fastq, but I encountered an error:…

Continue Reading Is there a way to run MiXCR with fasta sequences

MACROGEN

Macrogen provides personalized single cell multi-omics analysis services based on extensive experience and innovation. Single-cell gene sequencing is used to analyze gene expression profile and genetic changes in a single cell, which is a functional and structural unit of an organism. As it becomes possible to determine cellular heterogeneity, rare…

Continue Reading MACROGEN

Partial thyroid hormone-binding globulin deficiency

Introduction Thyroxine-binding globulin (TBG) is the main binding protein of the thyroid hormone in the human body. It combines around 75% of thyroxine (T4) and 70% of triiodofoxygen (T3).1 Thyroxine-binding globulin deficiency is a rare thyroid disease, mostly caused by a gene mutation, and is generally acquired through X-linked recessive…

Continue Reading Partial thyroid hormone-binding globulin deficiency

Primary Diffuse Large B-Cell Lymphoma of the Penis

Background Diffuse large B cell lymphoma (DLBCL) is the most common B lymphoid malignancy disorder, representing more than 30% of non-Hodgkin’s lymphoma.1 Although typical morphology is characterized by the diffuse or sheet-like proliferation of mature large B cells, DLBCL is a class of highly heterogeneous diseases exhibiting varying clinical and…

Continue Reading Primary Diffuse Large B-Cell Lymphoma of the Penis

Treatment of adults with relapsed or refractory DLBCL

Introduction Diffuse Large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), accounting for 31% of NHL cases in Western countries.1,2 The median age at presentation is 66, and 5-year survival rates decrease by age from 78% for those younger than 55 years to 54% for those over 65…

Continue Reading Treatment of adults with relapsed or refractory DLBCL

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma (mRCC), according to findings from a single-center study presented at the 2023 Kidney Cancer…

Continue Reading Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

Can Pre-Op MRI Staging Help Predict Prostate Cancer Recurrence after a Prostatectomy?

Emerging research suggests that pre-operative magnetic resonance imaging (MRI) findings may have comparable predictive efficacy to post-prostatectomy pathologic staging in assessing the risk of biochemical recurrence (BCR) of prostate cancer (PCa). For the retrospective study, recently published in the American Journal of Roentgenology, researchers assessed findings of extraprostatic extension (EPE)…

Continue Reading Can Pre-Op MRI Staging Help Predict Prostate Cancer Recurrence after a Prostatectomy?

B-cell-specific checkpoint molecules that regulate anti-tumour immunity

Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013). Article  CAS  PubMed …

Continue Reading B-cell-specific checkpoint molecules that regulate anti-tumour immunity

Diffuse Large B-Cell Lymphoma Market expected to rise

PRESS RELEASE Published June 20, 2023 “Diffuse Large B-Cell Lymphoma Market” DelveInsight’s “Diffuse Large B-cell Lymphoma – Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain,…

Continue Reading Diffuse Large B-Cell Lymphoma Market expected to rise

Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL

An improvement in minimal residual disease (MRD)-negative complete remission (CR) rate was observed with ponatinib (Iclusig) plus reduced-intensity chemotherapy vs imatinib (Gleevec) plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Findings come from the phase 3 PhALLCON trial (NCT03589326) which were presented at…

Continue Reading Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL

Chronic myeloid leukemia survey signals unmet need for patients

Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs in CML (CML SUN), which investigated how patients and physicians felt about current treatment options, joint decision-making, and treatment satisfaction,…

Continue Reading Chronic myeloid leukemia survey signals unmet need for patients

Bioconductor Unevensamplesizes

Answer: multiple filters in biomaRt by RuBBiT0 &utrif; 10 First, yes, one gene could be related to several GO ID, and the result is based on the annotation package you use. Second, could you pro… Comment: Diffbind “No genome detected” by kyliecode • 0 Hi Dr. Stark, Thanks very…

Continue Reading Bioconductor Unevensamplesizes

BCR/TCR analysis using target capture sequencing data

BCR/TCR analysis using target capture sequencing data 0 Hi all, MIXCR is widely used to analyze the TCR/BCR sequencing data, which usually use the multiplex amplicon sequencing method. We have design the 120bp probe to capture all the genes across IGH/IGL/IGK and TCR locus. Since the latest mixcr v4 used…

Continue Reading BCR/TCR analysis using target capture sequencing data

Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

Introduction Human immunodeficiency virus (HIV) infection is associated with an increased risk of hematological malignancy. Lymphoid neoplasms, particularly non-Hodgkin lymphoma, are the main hematologic malignancies that occur more frequently in connection with HIV infection non-Hodgkin lymphoma (NHL).1 Lymphomas are neoplastic lesions of the lymphoid system. According to World Health Organization…

Continue Reading Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

Bioconductor BasicWorkflow

Comment: DoparParam() execution fails when foreach() works by boris • 0 Registration allows me to use ClusterMQ as the backend for foreach/BiocParallel, linking to SLURM and unlocking far larger compute resource… Comment: TCGAbiolinks cannot find bcr_patient_barcode by Habil Zare &utrif; 170 Have you increased the version so that it builds…

Continue Reading Bioconductor BasicWorkflow

Featuring Secura Bio, Genmab, Genentech, Acerta Pharma & Vincerx Pharma

Company Logo Dublin, May 23, 2023 (GLOBE NEWSWIRE) — The “Richter’s Syndrome – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com‘s offering. This report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Richter’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and…

Continue Reading Featuring Secura Bio, Genmab, Genentech, Acerta Pharma & Vincerx Pharma

Richter’s Syndrome Pipeline Insight Report 2023: Featuring

Dublin, May 23, 2023 (GLOBE NEWSWIRE) — The “Richter’s Syndrome – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com‘s offering. This report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Richter’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage…

Continue Reading Richter’s Syndrome Pipeline Insight Report 2023: Featuring

The EMBARK Trial: An Interview With Neal D. Shore, MD

During a plenary session at the American Urological Association’s 2023 Annual Scientific Meeting, Neal D. Shore, MD, FACS, Director, CPI, of Carolina Urologic Research Center, and a CMO with GenesisCare, US in Myrtle Beach, South Carolina, presented findings from the phase 3 EMBARK trial demonstrating a strong oncologic benefit of…

Continue Reading The EMBARK Trial: An Interview With Neal D. Shore, MD

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5 | Blood Advances

B-cell receptor (BCR) signaling is essential for the diffuse large B-cell lymphoma (DLBCL) subtype that originates from activated B-cells (ABC). ABC-DLBCL cells are sensitive to Bruton tyrosine kinase intervention. However, relapsed or refractory ABC-DLBCL patients had overall response rates of 33-37% for Bruton tyrosine kinase inhibitors, suggesting the evaluation of…

Continue Reading BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5 | Blood Advances

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Cells and cell culture KOPN30, BV173, and K562 are BCR/ABL1-positive leukemia cell lines. All leukemia cell lines, as well as Ba/F3 cells, were maintained in RPMI-1640 medium supplemented with 15% fetal bovine serum (FBS) and penicillin–streptomycin (100 U/mL) at 37 °C in an atmosphere containing 5% CO2. KOPN30 cells were obtained…

Continue Reading Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference

AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference GUILFORD, Conn., May 09, 2023 (GLOBE NEWSWIRE) — AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today Dr Antje Prasse of Fraunhofer ITEM and Hannover Medical School, Germany, will present…

Continue Reading AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference

Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first patient with Thyroid Eye Disease (TED) has…

Continue Reading Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

TCGA CNV data 1p/19q codeletion (whole arm deletion)

TCGA CNV data 1p/19q codeletion (whole arm deletion) 2 Hi, you implied that you have already obtained the data. So, please proceed with your analysis. You will have to develop some code that identifies deletion of the entire chromosomal arms. You can create rules that define whether an arm is…

Continue Reading TCGA CNV data 1p/19q codeletion (whole arm deletion)

Need to specify “–chemistry” argument in “cellranger count”

I’m using CellRanger to analyze some RNA-seq data I have but I’m having a bit of trouble knowing if I’m doing the preprocessing steps correctly. This is the folder of Fastqs that I have: Control_GEX_S1_L003_I1_001.fastq.gz Treatment_BCR_S6_L004_R2_001.fastq.gz Control_GEX_S1_L003_I2_001.fastq.gz Treatment_GEX_S2_L003_I1_001.fastq.gz Control_GEX_S1_L003_R1_001.fastq.gz Treatment_GEX_S2_L003_I2_001.fastq.gz Control_GEX_S1_L003_R2_001.fastq.gz Treatment_GEX_S2_L003_R1_001.fastq.gz Control_GEX_S1_L004_I1_001.fastq.gz Treatment_GEX_S2_L003_R2_001.fastq.gz Control_GEX_S1_L004_I2_001.fastq.gz Treatment_GEX_S2_L004_I1_001.fastq.gz Control_GEX_S1_L004_R1_001.fastq.gz Treatment_GEX_S2_L004_I2_001.fastq.gz Control_GEX_S1_L004_R2_001.fastq.gz Treatment_GEX_S2_L004_R1_001.fastq.gz…

Continue Reading Need to specify “–chemistry” argument in “cellranger count”

Enzalutamide Plus Leuprolide Improves Metastasis-Free Survival in nmCSPC

Image Credit: © SciePro – Adobe Stock Patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) who received enzalutamide (Xtandi) plus leuprolide had a lower risk of metastasis or death vs those who did not receive enzalutamide, according to a press release from Astellas Pharmaceuticals.1 Results of the phase 3 EMBARK study…

Continue Reading Enzalutamide Plus Leuprolide Improves Metastasis-Free Survival in nmCSPC

Enzalutamide plus leuprolide reduces risk of metastasis by nearly 60% in nonmetastatic HSPC

Findings from the phase 3 EMBARK trial showed that enzalutamide (Xtandi) plus leuprolide reduced the risk of metastasis or death by nearly 60% vs placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR).1,2 “The EMBARK study is a phase 3 trial exploring the potential of…

Continue Reading Enzalutamide plus leuprolide reduces risk of metastasis by nearly 60% in nonmetastatic HSPC

Diffuse Large B-Cell Lymphoma Pipeline Report Provides the Assessment of Mono and Combination Therapies by Stage

PRESS RELEASE Published April 24, 2023 DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including Diffuse Large B-Cell Lymphoma clinical trials…

Continue Reading Diffuse Large B-Cell Lymphoma Pipeline Report Provides the Assessment of Mono and Combination Therapies by Stage

2023-04-17 | Press Release | Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the final analysis results of ORIENT-16, the Phase 3…

Continue Reading 2023-04-17 | Press Release | Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that the final analysis results of ORIENT-15, the Phase…

Continue Reading Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China , April 17, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the final analysis results of ORIENT-16, the Phase…

Continue Reading the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that the final analysis results of ORIENT-15, the Phase…

Continue Reading the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

New Products Posted to GenomeWeb: Akoya Biosciences, PCR Biosystems, Bruker, Molecular Designs, More

Akoya Biosciences PhenoCode Discovery Panels and Enable Cloud Platform Akoya Biosciences has launched PhenoCode Discovery Panels to simplify spatial biology workflows on the company’s PhenoCycler-Fusion platform. The ready-to-use, modular panels include biomarkers that can answer key biological questions related to immune profiling, lymphocyte profiling, tissue architecture, and immune activation and proliferation,…

Continue Reading New Products Posted to GenomeWeb: Akoya Biosciences, PCR Biosystems, Bruker, Molecular Designs, More

Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma

Introduction Cholangiocarcinoma (CC) is a form of gastrointestinal cancer that originates from the epithelium of either intrahepatic or extrahepatic bile ducts. It accounts for approximately 3% of all gastrointestinal cancers, with reported incidence of one to two cases per 100,000 persons per year in the USA (and much higher incidence…

Continue Reading Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma

Cellecta releases of NGS assays for T-cell and B-cell receptor chains

Genomics company Cellecta announced on Wednesday that it has launched its DriverMap Adaptive Immune Receptor DNA (AIR-DNA) TCR and BCR kits that provide rapid, single-tube polymerase chain reaction (PCR) analysis of the variability of T-cell and B-cell receptor chains from a range of sample types, including tissue biopsy, whole blood,…

Continue Reading Cellecta releases of NGS assays for T-cell and B-cell receptor chains

Inverted log2foldchange in study?

Hi guys, I’m relatively new to any type of analytics work and Rstudio. However, when inputting my TCGA data and doing all of the basic steps, my volcano plot and log2foldchange values seem to all be the opposite of what was expected. I understand perhaps this could just be the…

Continue Reading Inverted log2foldchange in study?

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, March 21, 2023  /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data from multiple trials in relation to…

Continue Reading Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023

Pfizer (PFE) and Astellas Report Phase 3 Study Shows XTANDI plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer…

Continue Reading Pfizer (PFE) and Astellas Report Phase 3 Study Shows XTANDI plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Enzalutamide plus leuprolide boosts metastasis-free survival in nmHSPC

Adding enzalutamide (Xtandi) to leuprolide significantly improved metastasis-free survival (MFS) vs leuprolide alone in patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence (BCR), according to topline findings from the phase 3 EMBARK trial (NCT02319837).1 Treatment with the enzalutamide/leuprolide regimen also led to statistically significant improvements in time…

Continue Reading Enzalutamide plus leuprolide boosts metastasis-free survival in nmHSPC

Pfizer, Astellas’ Xtandi meets main goal in phase 3 trial for prostate cancer subtype

Jeenah Moon/Getty Images News Pfizer (NYSE:PFE) and Astellas Pharma’s (OTCPK:ALPMF) (OTCPK:ALPMY) Xtandi met the main goal of a phase 3 trial to treat men with non-metastatic hormone-sensitive prostate cancer (nmHSPC). The late-stage study, dubbed EMBARK, enrolled 1,068 patients with nmHSPC (also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with…

Continue Reading Pfizer, Astellas’ Xtandi meets main goal in phase 3 trial for prostate cancer subtype

Pfizer and Astellas Report Phase 3 Study Shows XTANDI plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

© Reuters. Pfizer Inc. (NYSE:) and Astellas Pharma Inc. today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial…

Continue Reading Pfizer and Astellas Report Phase 3 Study Shows XTANDI plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

Review . 2023 Feb 25;15:245-255. doi: 10.2147/CMAR.S400013. eCollection 2023. Affiliations Expand Affiliation 1 Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People’s Republic of China. Item in Clipboard Review Jing Zhang et al. Cancer Manag Res. 2023. Show details Display options Display options Format AbstractPubMedPMID . 2023…

Continue Reading Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

KEGG ENZYME: 1.4.3.19

Entry EC 1.4.3.19                 Enzyme                                  Name Class Oxidoreductases;Acting on the CH-NH2 group of donors;With oxygen as acceptorBRITE hierarchy Sysname glycine:oxygen oxidoreductase (deaminating) Reaction(IUBMB) glycine + H2O + O2 = glyoxylate + NH3 + H2O2 (overall reaction) [RN:R00366]; (1a) glycine + O2 = 2-iminoacetate + H2O2 [RN:R07463]; (1b) 2-iminoacetate + H2O = glyoxylate +…

Continue Reading KEGG ENZYME: 1.4.3.19

Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants

Data reporting No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Study approval This study and all the relevant experiments were approved by Guangzhou Eighth People’s Hospital Ethics Committee (No. 202001134 and 202115202)….

Continue Reading Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants

DLBCL therapeutic strategies and gene-oriented treatment

Background Lymphoma is a group of heterogeneous hematological malignancies, which are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. DLBCL can be divided into germinal center B-cell-like (GCB) subgroup and non-GCB subgroup according to the origin of cells….

Continue Reading DLBCL therapeutic strategies and gene-oriented treatment

KEGG ENZYME: 1.7.1.4

Entry EC 1.7.1.4                  Enzyme                                  Name nitrite reductase [NAD(P)H];nitrite reductase (reduced nicotinamide adenine dinucleotide (phosphate));assimilatory nitrite reductase (ambiguous);nitrite reductase [NAD(P)H2];NAD(P)H2:nitrite oxidoreductase;nit-6 (gene name) Class Oxidoreductases;Acting on other nitrogenous compounds as donors;With NAD+ or NADP+ as acceptorBRITE hierarchy Sysname ammonia:NAD(P)+ oxidoreductase Reaction(IUBMB) NH3 + 3 NAD(P)+ + 2 H2O = nitrite + 3 NAD(P)H…

Continue Reading KEGG ENZYME: 1.7.1.4

Oxford Nanopore Extends Collaboration With UPS Healthcare, Illumina Delivers High Throughput Sequencing System to the Broad Institute, More

February 23, 2023 | Advanced machine learning provides objective tumor response assessments and unlocks novel biomarkers to predict patient outcomes; a comprehensive single-cell multi-omic solution enables the simultaneous exploration of the whole genome and whole mRNA transcriptome from the same single cell; cutting-edge generative AI models, proprietary wet-lab technologies, and…

Continue Reading Oxford Nanopore Extends Collaboration With UPS Healthcare, Illumina Delivers High Throughput Sequencing System to the Broad Institute, More

9 Common Questions About Cancer Biomarkers

Gene-targeted therapy and immunotherapy can be regarded as the most cutting-edge methods in current cancer treatment, saving the lives of many cancer patients. An essential indicator in these new types of cancer treatment is cancer biomarker testing. Here are answers to nine frequently asked questions about cancer markers. 1. What…

Continue Reading 9 Common Questions About Cancer Biomarkers

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis | Antibodies

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis Details Category: Antibodies Published on Thursday, 16 February 2023 11:15 Hits: 271 ROCKVILLE, MD, USA and SUZHOU, China I February 15, 2023 I Innovent Biologics, Group. (“Innovent”)…

Continue Reading Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis | Antibodies

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ — Innovent Biologics, Group. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient with moderate-to-severe plaque psoriasis has…

Continue Reading Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Table of Pharmacogenomic Biomarkers in Drug Labeling

  Abacavir Infectious Diseases HLA-B Boxed Warning, Dosage and Administration, Contraindications, Warnings and Precautions   Abemaciclib (1) Oncology ESR(Hormone Receptor) Indications and Usage, Adverse Reactions, Clinical Studies   Abemaciclib (2) Oncology ERBB2(HER2) Indications and Usage, Adverse Reactions, Clinical Studies   Abemaciclib (3) Oncology MKI67 Indications and Usage, Dosage and Administration,…

Continue Reading Table of Pharmacogenomic Biomarkers in Drug Labeling

Bioinformatics Analyst I Job in Maryland (MD), Other Career, Full Time Jobs in Frederick National Laboratory for Cancer Research

Bioinformatics Analyst I Job ID: req3323Employee Type: exempt full-timeDivision: Cancer Research Technology ProgramFacility: Frederick: ATRFLocation: 8560 Progress Dr, Frederick, MD 21701 USA The Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and operated by Leidos Biomedical Research, Inc….

Continue Reading Bioinformatics Analyst I Job in Maryland (MD), Other Career, Full Time Jobs in Frederick National Laboratory for Cancer Research

The Global Bioinformatics Market size is expected to reach $19.9 billion by 2028, rising at a market growth of 12.5% CAGR during the forecast period

ReportLinker In order to serve several fields of scientific study, including biomedicine, bioinformatics—a mix of biology and information technology—links biological data with methods for information storage, dissemination, and analysis. New York, Jan. 27, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Bioinformatics Market Size, Share &…

Continue Reading The Global Bioinformatics Market size is expected to reach $19.9 billion by 2028, rising at a market growth of 12.5% CAGR during the forecast period

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial | Blood Advances

Diffuse large B-cell lymphoma (DLBCL) with high co-expression of BCL2 and MYC proteins (double-expressor [DE] lymphoma), is considered an adverse prognostic indicator associated mostly with non-germinal center B-cell-like (non-GCB) DLBCL. BCL2/MYC overexpression is associated with B-cell receptor (BCR) pathway activation and, consequently, DE DLBCL may be sensitive to BCR inhibitors….

Continue Reading Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial | Blood Advances

Help and idea with TCR/BCR analysis

If you have non-enriched (I mean non-V(D)J-enriched, after emulsion) 5′ single-cell 10x data, prepared according to the 10x’s manual, then, very approximately, you should catch 30~50% of the T-cells, with 20~30% of the cells having both TRA+TRB chains (the main factor here seems to be the quality of size selection,…

Continue Reading Help and idea with TCR/BCR analysis

Chronic mucocutaneous candidiasis | CCID

1Department of Pediatrics, Affiliated Hospital of Weifang Medical University, Weifang, People’s Republic of China; 2Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, People’s Republic of China Correspondence: Weiyuan Ma, Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, People’s Republic of China, Tel +86-536-3081272, Email [email protected] Yongfeng…

Continue Reading Chronic mucocutaneous candidiasis | CCID

BOMIPROT

1 Bomi8228 Probetacellulin Q9TTC5 2 Bomi5121 Dimethylaniline monooxygenase [N-oxide-forming] 3/Dimethylaniline oxidase 3/Hepatic flavin-containing monooxygenase 3/Trimethylamine monooxygenase Q8HYJ9 3 Bomi10437 Uterine milk protein P46201 4 Bomi9179 Signal transducer and activator of transcription 5A/Mammary gland factor Q95115 5 Bomi9003 Selenoprotein P P49907 6 Bomi3613 Acetyl-CoA carboxylase 1 Q9TTS3 7 Bomi5003 Cytoskeleton-associated protein…

Continue Reading BOMIPROT

African ancestry GWAS of dementia in a large military cohort identifies significant risk loci

2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020. Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016;12:216–24. Article  Google Scholar  Matthews KA, Xu W, Gaglioti AH, Holt JB, Croft JB, Mack D, et al….

Continue Reading African ancestry GWAS of dementia in a large military cohort identifies significant risk loci

Scientific Manager – Immunology (Nanostring, Exome, RNA, CHIP) job with University of Texas MD Anderson Cancer Center

The Immunology department at MD Anderson Cancer Center seeks to determine the fundamental cellular and molecular mechanisms of a wide range of processes by which the body recognizes and eliminates pathogens and use these findings to unleash the patient’s own immune system against previously treatment-resistant cancers. Treating the immune system…

Continue Reading Scientific Manager – Immunology (Nanostring, Exome, RNA, CHIP) job with University of Texas MD Anderson Cancer Center

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma | Molecular Medicine

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. CAS  PubMed  Article  Google Scholar  Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large…

Continue Reading Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma | Molecular Medicine

Joint scRNAseq of B and T cells

Start Current SNIC Small Storage Projects SNIC 2022/23-318 Joint scRNAseq of B and T cells SUPR uses JavaScript for certain functions. We cannot guarantee that you will be able to use the system with JavaScript disabled. Primary Classification: 10605: Immunology (medical to be 30110 and agricultural to be 40302) Allocation…

Continue Reading Joint scRNAseq of B and T cells

Osteosarcoma Combination of Electroporation of Metabolic Modulators with Low dose chemotherapy

Osteosarcoma – Combination of Electroporation of Metabolic Modulators with Low dose chemotherapy Dr Kesh Gill Bone cancer particularly osteosarcoma can be an aggressive disease. Despite tremendous advances in diagnostic modalities, surgical procedures, and chemotherapy options, osteosarcoma confers a generally poor prognosis. The absence of an effective immune response to most…

Continue Reading Osteosarcoma Combination of Electroporation of Metabolic Modulators with Low dose chemotherapy

CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of…

Continue Reading CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

Transcriptional profiling of macrophages reveals distinct parasite stage-driven signatures during early infection by Leishmania donovani

Infection with L. donovani amastigotes or promastigotes promotes early changes in the mRNA pool of the host cell To compare the early effects of the two life stages L. donovani in the mature mRNA pool of the host cell, total cytosolic mRNA extracts from bone marrow-derived macrophage (BMDM) cultures infected…

Continue Reading Transcriptional profiling of macrophages reveals distinct parasite stage-driven signatures during early infection by Leishmania donovani

The Clinical Importance of Immunogenetics

Immunogenetics describes the investigation of the genetics underpinning the immune system and its responses. Its overall goal is to identify the specific genes responsible for encoding immunological cells and molecules. DNA. Image Credit: vitstudio/Shutterstock.com Linking genetics with immune dysregulation Immunogenetics is highly pertinent to a plethora of…

Continue Reading The Clinical Importance of Immunogenetics

KEGG ENZYME: 1.14.12.17

Entry EC 1.14.12.17               Enzyme                                  Name nitric oxide dioxygenase Class Oxidoreductases;Acting on paired donors, with incorporation or reduction of molecular oxygen;With NADH or NADPH as one donor, and incorporation of two atoms of oxygen into the other donorBRITE hierarchy Sysname nitric oxide,NAD(P)H:oxygen oxidoreductase Reaction(IUBMB) 2 nitric oxide + 2 O2 + NAD(P)H =…

Continue Reading KEGG ENZYME: 1.14.12.17

Precision Oncology – Data Scientist – Principal Scientist, Immuno-Oncology Bioinformatics at Sanofi

  Position Overview: We seek an experienced computational biologist / data scientist to identify and advance new immuno-oncology therapies for solid tumors and hematological malignancies. In this hands-on role, you will work as an integral part of project teams to identify targets, advance programs, and develop and test actionable biomarker strategies for…

Continue Reading Precision Oncology – Data Scientist – Principal Scientist, Immuno-Oncology Bioinformatics at Sanofi

Honeycomb Biotechnologies hiring Bioinformatics Scientist, Single-Cell Genomics in Waltham, Massachusetts, United States

Company Description:  Honeycomb Biotechnologies is an early-stage company focused on making scalable solutions for storage and single cell genomic analysis of precious clinical samples. We enable translation of the rich biological information encoded in clinical specimens into high-resolution digital information, which can be queried and analyzed with sequencing. The resulting…

Continue Reading Honeycomb Biotechnologies hiring Bioinformatics Scientist, Single-Cell Genomics in Waltham, Massachusetts, United States